Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2002

A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.

Beata Bolewska, Jacek Adamek, Jacek Juszczyk, Andrzej Gładysz, Khalil Nazzal, Janusz Cianciara, Franciszek Król, Włodzimierz Mazur, Barbara Czajka, Katarzyna Swietek, Wiesław Kryczka, Zbigniew Gonciarz

Med Sci Monit 2002; 8(4): CR257-262 :: ID: 420871

Abstract

BACKGROUND: Patients with on-going HBV viral replication often presentwith clinical features of active chronic hepatitis. Until the recent introduction of nucleoside analogues,interferon-alpha was the only approved drug for these patients. One of the former drugs, lamivudine,has been shown in clinical trials in the US and Asia to effectively inhibit the viral polymerase of HBV.Our study was undertaken to assess the efficacy and safety of lamivudine therapy in Polish patients withchronic hepatitis B. MATERIAL/METHODS: Forty-five patients with chronic hepatitis B (HBeAg positive,anti-e negative, HBV-DNA positive by hybridization assay) were enrolled in the study. The patients received100mg of lamivudine orally, once daily for 12 months. They returned for routine clinical and laboratorycontrol every two weeks during the first months of treatment, and later at 3-month intervals while receivinglamivudine. RESULTS: At the end of treatment, serum HBeAg was not detected in 21 patients (48.8%), andanti-HBe appeared in the serum of 19 patients. 37.2% of the patients in the study group showed sustainedsuppression of serum HBV DNA at the end of treatment. Lamivudine therapy was well tolerated, with therate of occurrence of adverse events similar to that observed in other clinical studies. CONCLUSIONS:12-month lamivudine therapy in this Polish population of patients with chronic hepatitis B induced ahigh rate of HBeAg seroconversion, accompanied by reduction of HBV-DNA and the normalization of alanineaminotransferase activities.

Keywords: Abdominal Pain, Alanine Transaminase, Angina Pectoris, Antiviral Agents, Biological Markers, bronchopneumonia, Colitis, Ulcerative, DNA, Viral, Gastrointestinal Diseases, Hepatitis B Antibodies, Hepatitis B e Antigens, Hepatitis B virus, Hepatitis B, Chronic, Lamivudine, Poland, Reverse Transcriptase Inhibitors, Safety, Urinary Tract Infections, Viral Load, Viremia, Virus Replication

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750